Travere Stock Based Compensation from 2010 to 2024

TVTX Stock

USD 17.91 0.77 4.12%

Travere Therapeutics Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation will likely drop to about 26.9 M in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2012-09-30

Previous Quarter

9.9 M

Current Value

8 M

Quarterly Volatility

57.4 M

Yuan Drop

Covid

Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.4 M, Selling General Administrative of 278.8 M or Other Operating Expenses of 548.1 M, as well as many indicators such as Price To Sales Ratio of 6.88, Dividend Yield of 0.0 or PTB Ratio of 3.16. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.

Check out the analysis of Travere Therapeutics Correlation against competitors.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Travere Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Travere Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Travere Stock Based Compensation Regression Statistics

	Arithmetic Mean	23,681,019
	Geometric Mean	20,003,360
	Coefficient Of Variation	42.40
	Mean Deviation	7,325,549
	Median	23,614,000
	Standard Deviation	10,041,041
	Sample Variance	100.8T
	Range	42.8M
	R-Value	0.71
	Mean Square Error	54.2T
	R-Squared	0.50
	Significance	0
	Slope	1,589,259
	Total Sum of Squares	1411.5T

Travere Stock Based Compensation History

	2024	26.9 M
	2023	44.2 M
	2022	38.1 M
	2021	29.6 M
	2020	23.6 M
	2019	21.1 M
	2018	19.8 M

Other Fundumenentals of Travere Therapeutics

Stock Based Compensation To Revenue

Travere Therapeutics Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Intangible Assets	Short Term Investments	Net Receivables	Good Will	Net Tangible Assets	Long Term Debt	Net Invested Capital	Net Working Capital	Property Plant Equipment	Short Long Term Debt	Capital Stock	Long Term Debt Total	Capital Surpluse
Total Assets		0.8	0.54	-0.68	0.6	0.85	0.99	0.2	0.94	0.2	0.86	0.96	0.39	-0.29	-0.35	0.72	0.72	0.74	0.37	-0.19	0.59	-0.19	0.53
Total Stockholder Equity	0.8		0.06	-0.22	0.34	0.46	0.75	0.28	0.63	0.49	0.85	0.67	0.6	-0.06	0.09	0.22	0.44	0.42	0.17	-0.07	0.15	-0.07	0.12
Net Debt	0.54	0.06		-0.94	0.79	0.88	0.59	-0.1	0.63	-0.37	0.28	0.71	-0.05	-0.79	-0.91	0.92	0.74	0.74	0.37	-0.69	0.84	-0.69	0.82
Retained Earnings	-0.68	-0.22	-0.94		-0.83	-0.94	-0.73	0.12	-0.78	0.33	-0.38	-0.8	0.03	0.75	0.82	-0.94	-0.8	-0.84	-0.49	0.64	-0.94	0.64	-0.9
Accounts Payable	0.6	0.34	0.79	-0.83		0.81	0.62	0.0	0.66	-0.19	0.43	0.71	0.05	-0.85	-0.76	0.72	0.69	0.68	0.26	-0.8	0.73	-0.8	0.75
Total Liab	0.85	0.46	0.88	-0.94	0.81		0.87	0.08	0.88	-0.09	0.66	0.91	0.15	-0.62	-0.71	0.92	0.81	0.84	0.44	-0.54	0.81	-0.54	0.77
Total Current Assets	0.99	0.75	0.59	-0.73	0.62	0.87		0.1	0.93	0.1	0.78	0.98	0.31	-0.34	-0.39	0.78	0.78	0.81	0.37	-0.22	0.66	-0.22	0.61
Short Term Debt	0.2	0.28	-0.1	0.12	0.0	0.08	0.1		0.22	0.74	0.5	0.04	0.29	0.07	0.16	-0.19	-0.08	-0.12	-0.3	0.06	-0.18	0.06	-0.12
Common Stock	0.94	0.63	0.63	-0.78	0.66	0.88	0.93	0.22		0.14	0.76	0.92	0.35	-0.39	-0.49	0.77	0.68	0.72	0.43	-0.25	0.72	-0.25	0.66
Current Deferred Revenue	0.2	0.49	-0.37	0.33	-0.19	-0.09	0.1	0.74	0.14		0.5	0.01	0.46	0.24	0.36	-0.36	-0.17	-0.23	-0.38	0.2	-0.35	0.2	-0.28
Intangible Assets	0.86	0.85	0.28	-0.38	0.43	0.66	0.78	0.5	0.76	0.5		0.72	0.54	-0.08	-0.14	0.37	0.4	0.4	0.23	-0.09	0.2	-0.09	0.16
Short Term Investments	0.96	0.67	0.71	-0.8	0.71	0.91	0.98	0.04	0.92	0.01	0.72		0.25	-0.46	-0.52	0.86	0.84	0.85	0.35	-0.33	0.72	-0.33	0.68
Net Receivables	0.39	0.6	-0.05	0.03	0.05	0.15	0.31	0.29	0.35	0.46	0.54	0.25		0.01	0.01	-0.06	-0.09	-0.1	0.14	0.0	-0.03	0.0	-0.07
Good Will	-0.29	-0.06	-0.79	0.75	-0.85	-0.62	-0.34	0.07	-0.39	0.24	-0.08	-0.46	0.01		0.81	-0.61	-0.62	-0.56	-0.2	0.95	-0.74	0.95	-0.78
Net Tangible Assets	-0.35	0.09	-0.91	0.82	-0.76	-0.71	-0.39	0.16	-0.49	0.36	-0.14	-0.52	0.01	0.81		-0.78	-0.46	-0.45	-0.3	0.69	-0.75	0.69	-0.74
Long Term Debt	0.72	0.22	0.92	-0.94	0.72	0.92	0.78	-0.19	0.77	-0.36	0.37	0.86	-0.06	-0.61	-0.78		0.83	0.85	0.46	-0.46	0.87	-0.46	0.82
Net Invested Capital	0.72	0.44	0.74	-0.8	0.69	0.81	0.78	-0.08	0.68	-0.17	0.4	0.84	-0.09	-0.62	-0.46	0.83		0.98	0.35	-0.54	0.76	-0.54	0.75
Net Working Capital	0.74	0.42	0.74	-0.84	0.68	0.84	0.81	-0.12	0.72	-0.23	0.4	0.85	-0.1	-0.56	-0.45	0.85	0.98		0.36	-0.49	0.81	-0.49	0.79
Property Plant Equipment	0.37	0.17	0.37	-0.49	0.26	0.44	0.37	-0.3	0.43	-0.38	0.23	0.35	0.14	-0.2	-0.3	0.46	0.35	0.36		-0.18	0.47	-0.18	0.24
Short Long Term Debt	-0.19	-0.07	-0.69	0.64	-0.8	-0.54	-0.22	0.06	-0.25	0.2	-0.09	-0.33	0.0	0.95	0.69	-0.46	-0.54	-0.49	-0.18		-0.59	1.0	-0.64
Capital Stock	0.59	0.15	0.84	-0.94	0.73	0.81	0.66	-0.18	0.72	-0.35	0.2	0.72	-0.03	-0.74	-0.75	0.87	0.76	0.81	0.47	-0.59		-0.59	0.97
Long Term Debt Total	-0.19	-0.07	-0.69	0.64	-0.8	-0.54	-0.22	0.06	-0.25	0.2	-0.09	-0.33	0.0	0.95	0.69	-0.46	-0.54	-0.49	-0.18	1.0	-0.59		-0.64
Capital Surpluse	0.53	0.12	0.82	-0.9	0.75	0.77	0.61	-0.12	0.66	-0.28	0.16	0.68	-0.07	-0.78	-0.74	0.82	0.75	0.79	0.24	-0.64	0.97	-0.64

Click cells to compare fundamentals

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	44.2 M	26.9 M
Stock Based Compensation To Revenue	0.30	0.24

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Travere Stock Based Compensation from 2010 to 2024

Latest Travere Therapeutics' Stock Based Compensation Growth Pattern

Travere Stock Based Compensation Regression Statistics

Travere Stock Based Compensation History

Other Fundumenentals of Travere Therapeutics

Travere Therapeutics Stock Based Compensation component correlations

About Travere Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Travere Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY